journal
https://read.qxmd.com/read/38606657/dietary-sodium-and-fluid-intake-in-heart-failure-a-clinical-consensus-statement-of-the-heart-failure-association-of-the-esc
#1
JOURNAL ARTICLE
Wilfried Mullens, Kevin Damman, Sebastiaan Dhont, Debasish Banerjee, Antoni Bayes-Genis, Antonio Cannata, Ovidiu Chioncel, Maja Cikes, Justin Ezekowitz, Andreas J Flammer, Pieter Martens, Alexandre Mebazaa, Robert J Mentz, Òscar Miró, Brenda Moura, Julio Nunez, Jozine M Ter Maaten, Jeffrey Testani, Roland van Kimmenade, Frederik H Verbrugge, Marco Metra, Giuseppe M C Rosano, Gerasimos Filippatos
Sodium and fluid restriction has traditionally been advocated in patients with heart failure (HF) due to their sodium and water avid state. However, most evidence regarding the altered sodium handling, fluid homeostasis and congestion-related signs and symptoms in patients with HF originates from untreated patient cohorts and physiological investigations. Recent data challenge the beneficial role of dietary sodium and fluid restriction in HF. Consequently, the European Society of Cardiology HF guidelines have gradually downgraded these recommendations over time, now advising for the limitation of salt intake to no more than 5 g/day in patients with HF, while contemplating fluid restriction of 1...
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606645/cause-specific-death-in-heart-failure-across-the-ejection-fraction-spectrum-a-comprehensive-assessment-of-over-100%C3%A2-000-patients-in-the-swedish-heart-failure-registry
#2
JOURNAL ARTICLE
Camilla Settergren, Lina Benson, Angiza Shahim, Ulf Dahlström, Tonje Thorvaldsen, Gianluigi Savarese, Lars H Lund, Bahira Shahim
AIM: To assess cause-specific death in patients with heart failure with preserved, mildly reduced, and reduced ejection fraction (HFpEF, HFmrEF, and HFrEF). METHODS AND RESULTS: Data were analysed from the Swedish Heart Failure Registry (SwedeHF) and the National Patient Register of patients enrolled in SwedeHF 2000-2021. Cox proportional hazards regression models were performed and adjusted for age, sex and time period. Among 100 584 patients (23% HFpEF, 23% HFmrEF, 53% HFrEF), median age (interquartile range) was 75 (66-82) and 36% were female...
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606584/heart-failure-and-respiratory-tract-infection-cause-and-consequence-of-acute-decompensation
#3
EDITORIAL
Bettina Heidecker, Matteo Pagnesi, Thomas F Lüscher
No abstract text is available yet for this article.
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606573/impact-of-guideline-directed-medical-therapy-on-systolic-blood-pressure-and-cardiovascular-outcomes-in-patients-with-heart-failure-and-low-blood-pressure-a-systematic-review-and-meta-analysis
#4
JOURNAL ARTICLE
Jingwei Li, Yunlong Chen, Yi Wang, Xiaoyan Liu, Ping Li, Yongming He, Yang Hao, Lan Huang, Jun Jin, Jiang Wang, Craig Anderson
AIMS: Existing research indicates that patients with heart failure (HF) may have restricted access to guideline-directed medical therapy (GDMT) when their blood pressure (BP) is comparatively low. However, recent clinical trials suggest that HF patients with low BP could still benefit from certain HF medications, which have a minimal impact on BP. This systematic review and meta-analysis was conducted to determine whether this applies to all GDMT. METHODS AND RESULTS: A systematic search of MEDLINE and EMBASE was conducted for studies published from inception to 10 January 2024...
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606555/baroreflex-activation-therapy-in-patients-with-heart-failure-and-a-reduced-ejection-fraction-long-term-outcomes
#5
JOURNAL ARTICLE
Michael R Zile, JoAnn Lindenfeld, Fred A Weaver, Faiez Zannad, Elizabeth Galle, Tyson Rogers, William T Abraham
AIMS: Carotid baroreflex activation therapy (BAT) restores baroreflex sensitivity and modulates the imbalance in cardiac autonomic function in patients with heart failure with reduced ejection fraction (HFrEF). We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides long-term safety and sustainable symptomatic improvement. METHODS AND RESULTS: BeAT-HF was a prospective, multicentre, randomized, two-arm, parallel-group, open-label, non-implanted control trial...
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606524/n-terminal-pro-b-type-natriuretic-peptide-post-discharge-monitoring-in-the-management-of-patients-with-heart-failure-and-preserved-ejection-fraction%C3%A2-%C3%A2-a-randomized-trial-the-nice-study
#6
JOURNAL ARTICLE
Domingo A Pascual-Figal, Alvaro Hernández-Vicente, Francisco Pastor-Pérez, Manuel Martínez-Sellés, Eduard Solé-González, Jesús Alvarez-García, Pablo García-Pavía, Alfonso Varela-Román, Pedro Luis Sánchez, Juan F Delgado, Jose A Noguera-Velasco, Antoni Bayes-Genis
AIMS: There is a lack of specific studies assessing the impact of natriuretic peptide monitoring in the post-discharge management of patients with heart failure (HF) and preserved ejection fraction (HFpEF), throughout the vulnerable phase following acute HF hospitalization. The NICE study aims to assess the clinical benefit of incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) into the post-discharge management of HFpEF patients. METHODS AND RESULTS: Individuals admitted with HFpEF (left ventricular ejection fraction >50%) were included in a multicentre randomized controlled study employing an open-label design with event blinding (NCT02807168)...
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606515/reply-to-the-pharmacist-ally-in-heart-failure-useful-when-involved
#7
LETTER
Craig J Beavers, Deepak L Bhatt, Gad Gotter
No abstract text is available yet for this article.
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38606485/left-atrial-to-coronary-sinus-shunting-for-treatment-of-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction-the-alt-flow-early-feasibility-study-1-year-results
#8
JOURNAL ARTICLE
Marcus A Urey, Benjamin Hibbert, Ulrich Jorde, Peter Eckman, Trevor Simard, Marino Labinaz, Babak Nazer, Mark Wiley, Bhanu Gupta, Andrew Sauer, Hirak Shah, Paul Sorajja, Andres M Pineda, Emil Missov, Ehtisham Mahmud, Rami Kahwash, Scott Lilly, Azeem Latib, Sandhya Murthy, Neil Fam, Santiago Garcia, Eugene S Chung, Liviu Klein, Richard Cheng, Brian A Houston, Nicholas S Amoroso, Lee Chang, Sameer Gafoor, Sunit-Preet Chaudhry, James Hermiller, Jonathan G Schwartz, Lillian Aldaia, Konstantinos Koulogiannis, William A Gray, Firas Zahr
AIMS: Patients with heart failure and mildly reduced or preserved ejection fraction have limited therapeutic options. The ALT-FLOW Early Feasibility Study evaluated safety, haemodynamics and outcomes for the APTURE transcatheter shunt system, a novel left atrium to coronary sinus shunt in these patients. METHODS AND RESULTS: Safety and shunt implantation success was evaluated for all 116 enrolled patients. An analysis population of implanted patients with a left ventricular ejection fraction (LVEF) >40% (n = 95) was chosen to assess efficacy via paired comparison between baseline and follow-up haemodynamic (3 and 6 months), and echocardiographic, clinical and functional outcomes (6 months and 1 year)...
April 12, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38602441/multimorbidity-in-the-era-of-increasing-life-expectancy-and-aging-population
#9
EDITORIAL
Nikhil Patel, Joseph Yeboah
No abstract text is available yet for this article.
April 11, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38587259/insulin-like-growth-factor-binding-protein-7-concentrations-in-chronic-heart-failure-results-from-the-emperor-programme
#10
JOURNAL ARTICLE
João Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Sandra González Maldonado, Marina Panova-Noeva, Mikhail Sumin, Serge Masson, Stuart J Pocock, Stefan D Anker, Faiez Zannad, James L Januzzi
AIMS: Insulin-like growth factor binding protein-7 (IGFBP7) is a biomarker of tissue senescence with a role in cardio-renal pathophysiology. The role of IGFBP7 as a prognostic biomarker across the full ejection fraction (EF) spectrum of heart failure (HF) remains less well understood. We examined associations between IGFBP7 and risk of cardio-renal outcomes regardless of EF and the effect of empagliflozin treatment on IGFBP7 concentrations among individuals with HF. METHODS AND RESULTS: IGFBP7 was measured in 1125 study participants from the EMPEROR-Reduced and EMPEROR-Preserved trials...
April 8, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38587090/effects-of-sacubitril-valsartan-according-to-polypharmacy-status-in-paragon-hf
#11
JOURNAL ARTICLE
Shingo Matsumoto, Mingming Yang, Li Shen, Alasdair Henderson, Brian L Claggett, Akshay S Desai, Martin Lefkowitz, Jean L Rouleau, Orly Vardeny, Michael R Zile, Pardeep S Jhund, Muthiah Vaduganathan, Scott D Solomon, John J V McMurray
AIMS: Patients with heart failure (HF) and preserved ejection fraction (HFpEF) have a particularly high prevalence of comorbidities, often necessitating treatment with many medications. The aim of this study was to evaluate the association between polypharmacy status and outcomes in PARAGON-HF. METHODS AND RESULTS: In this post hoc analysis, baseline medication status was available in 4793 of 4796 patients included in the primary analysis of PARAGON-HF. The effects of sacubitril/valsartan, compared with valsartan, were assessed according to the number of medications at baseline: 683 non-polypharmacy (<5 medications); 2750 polypharmacy (5-9 medications), and 1360 hyper-polypharmacy (≥10 medications)...
April 8, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38583036/comparative-effectiveness-of-sacubitril-valsartan-versus-angiotensin-converting-enzyme-inhibitors-angiotensin-receptor-blockers-in-patients-with-de-novo-heart-failure-with-mildly-reduced-and-preserved-ejection-fraction
#12
JOURNAL ARTICLE
Ankeet S Bhatt, Muthiah Vaduganathan, Barada Prasad Jena, Sylwia Suminska, Carlos Eid, Rahul Khairnar, Gabriella Farries, Michele Senni
No abstract text is available yet for this article.
April 7, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38576163/incidence-and-predictors-of-heart-failure-with-reduced-and-preserved-ejection-fraction-after-st-elevation-myocardial-infarction-in-the-contemporary-era-of-early-percutaneous-coronary-intervention
#13
JOURNAL ARTICLE
Chris Lenselink, Kim W L M Ricken, Hilde E Groot, Tijs J de Bruijne, Tom Hendriks, Pim van der Harst, Adriaan A Voors, Erik Lipsic
AIMS: The development and incidence of de-novo heart failure after ST-elevation myocardial infarction (STEMI) in the contemporary era of rapid reperfusion are largely unknown. We aimed to establish the incidence of post-STEMI heart failure, stratified by left ventricular ejection fraction (LVEF) and to find predictors for its occurrence. Furthermore, we investigated the course of left ventricular systolic and diastolic function after STEMI. METHODS AND RESULTS: A total of 1172 all-comer STEMI patients from the CardioLines Biobank were included...
April 4, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38572654/treatment-effects-of-empagliflozin-in-hospitalized-heart-failure-patients-across-the-range-of-left-ventricular-ejection-fraction%C3%A2-%C3%A2-results-from-the-empulse-trial
#14
JOURNAL ARTICLE
Jasper Tromp, Mikhail N Kosiborod, Christiane E Angermann, Sean P Collins, John R Teerlink, Piotr Ponikowski, Jan Biegus, João Pedro Ferreira, Michael E Nassif, Mitchell A Psotka, Martina Brueckmann, Jonathan P Blatchford, Dominik Steubl, Adriaan A Voors
AIM: The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of patients hospitalized for acute heart failure (HF). We investigated whether efficacy and safety of empagliflozin were consistent across the spectrum of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: A total of 530 patients hospitalized for acute de novo or decompensated HF were included irrespective of LVEF...
April 4, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38571456/congestion-patterns-in-severe-tricuspid-regurgitation-and-transcatheter-treatment-insights-from-a-multicentre-registry
#15
JOURNAL ARTICLE
Karl-Philipp Rommel, Guillaume Bonnet, Vera Fortmeier, Lukas Stolz, Anne R Schöber, Jennifer von Stein, Mohammad Kassar, Muhammed Gerçek, Sebastian Rosch, Thomas J Stocker, Maria I Körber, Karl-Patrik Kresoja, Tanja K Rudolph, Roman Pfister, Stephan Baldus, Stephan Windecker, Holger Thiele, Fabien Praz, Jörg Hausleiter, Volker Rudolph, Daniel Burkhoff, Philipp Lurz
AIMS: While invasively determined congestion holds mechanistic and prognostic significance in acute heart failure (HF), its role in patients with tricuspid regurgitation (TR)-related right- heart failure (HF) undergoing transcatheter tricuspid valve intervention (TTVI) is less well established. A comprehensive understanding of congestion patterns might aid in procedural planning, risk stratification, and the identification of patients who may benefit from adjunctive therapies before undergoing TTVI...
April 4, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38562026/sodium-glucose-cotransporter-2-inhibitors-and-skeletal-muscle
#16
EDITORIAL
Andrew J Stewart Coats
No abstract text is available yet for this article.
April 1, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38562007/circulating-levels-of-carbohydrate-antigen-125-in-chronic-heart-failure-useful-or-futile
#17
EDITORIAL
Herminio Morillas, Julio Núñez, Pedro Moliner
No abstract text is available yet for this article.
April 1, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38561983/comorbidities-and-cardiac-resynchronization-therapy-do-we-talk-the-talk-or-should-we-walk-the-walk
#18
EDITORIAL
Domenico D'Amario, Renzo Laborante, Pasquale Santangeli
No abstract text is available yet for this article.
April 1, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38561314/interatrial-shunt-therapy-in-advanced-heart-failure-outcomes-from-the-open-label-cohort-of-the-relieve-hf-trial
#19
JOURNAL ARTICLE
Josep Rodés-Cabau, JoAnn Lindenfeld, William T Abraham, Michael R Zile, Saibal Kar, Antoni Bayés-Genís, Neal Eigler, Richard Holcomb, Julio Núñez, Elizabeth Lee, Michal Laufer Perl, Gil Moravsky, Michael Pfeiffer, John Boehmer, John Gorcsan, Jeroen J Bax, Stefan Anker, Gregg W Stone
AIMS: Heart failure (HF) outcomes remain poor despite optimal guideline-directed medical therapy (GDMT). We assessed safety, effectiveness, and transthoracic echocardiographic (TTE) outcomes during the 12 months after Ventura shunt implantation in the RELIEVE-HF open-label roll-in cohort. METHODS AND RESULTS: Eligibility required symptomatic HF despite optimal GDMT with ≥1 HF hospitalization in the prior year or elevated natriuretic peptides. The safety endpoint was device-related major adverse cardiovascular or neurological events at 30 days, compared to a prespecified performance goal...
April 1, 2024: European Journal of Heart Failure
https://read.qxmd.com/read/38560762/cost-effectiveness-of-remote-haemodynamic-monitoring-by-an-implantable-pulmonary-artery-pressure-monitoring-sensor-cardiomems-hf-system-in-chronic-heart-failure-in-the-netherlands
#20
JOURNAL ARTICLE
Hamraz Mokri, Pascal R D Clephas, Rudolf A de Boer, Pieter van Baal, Jasper J Brugts, Maureen P M H Rutten-van Mölken
AIMS: Remote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost-effectiveness analyses studying the value of remote haemodynamic monitoring in a European healthcare system with a contemporary standard care group are lacking. METHODS AND RESULTS: A Markov model was developed to estimate the cost-effectiveness of PA-guided therapy compared to the standard of care based upon patient-level data of the MONITOR-HF trial performed in the Netherlands in patients with chronic HF (New York Heart Association class III and at least one previous HF hospitalization)...
April 1, 2024: European Journal of Heart Failure
journal
journal
34664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.